Benign prostatic hyperplasia affects roughly half of all men by age 60 and up to 90 percent of men by age 85. The prostate gland, which sits just below the bladder and surrounds the urethra, gradually enlarges throughout a man's adult life. When that enlargement compresses the urethra enough to interfere with urinary flow, doctors diagnose BPH and begin discussing treatment options.
For many men, medication is the first line of defense. But the landscape of BPH drugs can feel confusing — alpha-blockers, 5-alpha reductase inhibitors, combination therapies, and newer agents each work differently and carry distinct side effect profiles. Understanding how these medications compare helps you have a more productive conversation with your urologist and feel confident about the treatment path you choose.
How BPH Causes Urinary Symptoms
The prostate gland produces fluid that nourishes and transports sperm. During puberty, testosterone and its more potent derivative dihydrotestosterone (DHT) drive the prostate's initial growth. After age 25, the prostate begins a second growth phase that continues for the rest of a man's life.
As the prostate enlarges, it squeezes the urethra like a clamp around a garden hose. This mechanical compression creates what urologists call "static" obstruction. Simultaneously, the smooth muscle within the prostate and bladder neck can contract excessively, adding "dynamic" obstruction on top of the physical blockage.
Together, these two mechanisms produce the cluster of symptoms known as lower urinary tract symptoms, or LUTS. These include a weak or intermittent urinary stream, difficulty starting urination, the sensation of incomplete bladder emptying, frequent urination especially at night (nocturia), and urgency that sometimes leads to leakage. The severity of these symptoms, rather than the actual size of the prostate, typically guides treatment decisions.
Alpha-Blockers: Relaxing the Squeeze
Alpha-blockers represent the most commonly prescribed first-line medications for BPH. They work by blocking alpha-1 adrenergic receptors in the smooth muscle of the prostate and bladder neck, effectively relaxing the dynamic component of urethral obstruction. Because they address muscle tension rather than prostate size, alpha-blockers provide noticeable symptom relief within days to weeks.
Commonly Prescribed Alpha-Blockers
Tamsulosin (Flomax) is the most widely prescribed alpha-blocker for BPH worldwide. It selectively targets alpha-1A receptors concentrated in the prostate, which theoretically reduces side effects compared to non-selective alternatives. The standard dose is 0.4 milligrams taken once daily, usually 30 minutes after the same meal each day. Most men notice improved urinary flow within one to two weeks.
Alfuzosin (Uroxatral) is another selective alpha-blocker taken as a 10-milligram extended-release tablet once daily after a meal. Clinical trials show it provides similar efficacy to tamsulosin with a comparable side effect profile.
Silodosin (Rapaflo) offers the highest selectivity for alpha-1A receptors among available options. Taken at 8 milligrams once daily with a meal, it provides rapid symptom relief. However, its extreme selectivity comes with a notable trade-off — retrograde ejaculation occurs in up to 28 percent of men taking silodosin, significantly higher than with other alpha-blockers.
Doxazosin (Cardura) and terazosin (Hytrin) are older, non-selective alpha-blockers that block receptors throughout the body, not just in the prostate. They require dose titration starting from low doses and carry a higher risk of dizziness, fatigue, and drops in blood pressure. These agents are sometimes chosen when a man has both BPH and hypertension, since they address both conditions simultaneously.
Side Effects of Alpha-Blockers
The most common side effects across all alpha-blockers include dizziness, orthostatic hypotension (a sudden drop in blood pressure upon standing), nasal congestion, and fatigue. These effects tend to be most noticeable during the first few weeks of treatment and often diminish over time.
A particularly important consideration is intraoperative floppy iris syndrome (IFIS), a condition where the iris becomes flaccid during cataract surgery. Men taking or who have ever taken tamsulosin should inform their ophthalmologist before any eye surgery.
Ejaculatory dysfunction, including reduced ejaculate volume or retrograde ejaculation, affects roughly 4 to 11 percent of men on tamsulosin and up to 28 percent on silodosin. This side effect is reversible upon stopping the medication.
5-Alpha Reductase Inhibitors: Shrinking the Prostate
While alpha-blockers relax muscle tension, 5-alpha reductase inhibitors (5-ARIs) take a fundamentally different approach — they actually shrink the prostate gland by blocking the conversion of testosterone into DHT. Since DHT is the primary hormonal driver of prostate growth, reducing DHT levels causes the prostate to gradually decrease in volume by 20 to 30 percent over six to twelve months.
Available 5-Alpha Reductase Inhibitors
Finasteride (Proscar) inhibits type II 5-alpha reductase, the enzyme primarily responsible for DHT production in the prostate. Taken at 5 milligrams daily, finasteride reduces serum DHT levels by approximately 70 percent. The same drug at a lower dose (1 milligram, marketed as Propecia) is used for male pattern baldness.
Dutasteride (Avodart) inhibits both type I and type II 5-alpha reductase enzymes, producing a more complete suppression of DHT — roughly 90 percent reduction compared to finasteride's 70 percent. The standard dose is 0.5 milligrams daily. Dutasteride has an extremely long half-life of approximately five weeks, meaning its effects persist long after discontinuation.
When 5-ARIs Make Sense
According to the American Urological Association-guideline), 5-ARIs are most appropriate for men with demonstrably enlarged prostates (typically greater than 30 to 40 grams) or elevated prostate-specific antigen (PSA) levels suggesting significant prostatic enlargement. In men with smaller prostates, the benefit of 5-ARIs is minimal because there is less tissue to shrink.
The major drawback of 5-ARIs is their slow onset of action. Unlike alpha-blockers, which work within weeks, 5-ARIs require three to six months of continuous use before producing meaningful symptom improvement. Full benefit may not be apparent for up to a year.
Side Effects of 5-Alpha Reductase Inhibitors
Sexual side effects are the primary concern with 5-ARIs. Clinical trials report erectile dysfunction in approximately 5 to 8 percent of men, decreased libido in 3 to 6 percent, and reduced ejaculate volume in about 4 percent. These side effects are generally reversible after stopping the medication, though a small number of men report persistent symptoms — a controversial condition some call "post-finasteride syndrome."
An important clinical consideration is that 5-ARIs reduce PSA levels by approximately 50 percent. Urologists must account for this when interpreting PSA screening results for prostate cancer. If you are taking a 5-ARI, your doctor should double your measured PSA value to estimate what it would be without medication.
Gynecomastia (breast tissue enlargement) and breast tenderness occur in roughly 1 to 2 percent of men taking 5-ARIs. This side effect is typically mild but can be distressing.
Combination Therapy: Using Both Drug Classes Together
For men with moderate to severe symptoms and significantly enlarged prostates, combining an alpha-blocker with a 5-ARI offers greater benefit than either medication alone. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that combination therapy reduced the risk of BPH progression by 66 percent, compared to 39 percent with doxazosin alone and 34 percent with finasteride alone.
The most common combination is tamsulosin plus dutasteride, available as a single capsule marketed as Jalyn. This combination provides the rapid symptom relief of the alpha-blocker while the 5-ARI works gradually to shrink the prostate and reduce the long-term risk of acute urinary retention and the need for surgical intervention.
The trade-off is straightforward — combination therapy carries the side effects of both drug classes. Men on combination therapy experience higher rates of dizziness, ejaculatory dysfunction, erectile dysfunction, and decreased libido compared to either drug alone.
Research published in the New England Journal of Medicine from the CombAT study confirmed that combination therapy was superior to monotherapy for reducing symptom progression, acute urinary retention, and BPH-related surgery over a four-year follow-up period.
Phosphodiesterase-5 Inhibitors: A Newer Option
Tadalafil (Cialis) at a daily dose of 5 milligrams is FDA-approved for treating BPH symptoms, either alone or in combination with finasteride. Originally developed for erectile dysfunction, tadalafil relaxes smooth muscle in the prostate, bladder, and blood vessels through a mechanism distinct from alpha-blockers.
Clinical trials show that daily tadalafil improves International Prostate Symptom Score (IPSS) by roughly 2 to 3 points compared to placebo — a modest but statistically significant benefit. The drug is particularly appealing for men who experience both BPH symptoms and erectile dysfunction, as it addresses both conditions with a single medication.
Side effects include headache, back pain, nasal congestion, and indigestion. Unlike alpha-blockers, tadalafil does not typically cause dizziness or orthostatic hypotension, though it should not be combined with nitrate medications used for chest pain.
Anticholinergics and Beta-3 Agonists: Addressing Storage Symptoms
Some men with BPH experience predominantly "storage" symptoms — urgency, frequency, and nocturia — rather than "voiding" symptoms like weak stream and hesitancy. When storage symptoms persist despite alpha-blocker therapy, doctors may add an anticholinergic medication such as oxybutynin, tolterodine, or solifenacin, or a beta-3 agonist like mirabegron (Myrbetriq).
These medications calm an overactive bladder muscle, reducing the sudden contractions that create urgency and frequency. However, anticholinergics must be used cautiously in men with BPH because they can theoretically worsen urinary retention. Beta-3 agonists carry a lower risk of retention and are increasingly preferred in this population.
Common anticholinergic side effects include dry mouth, constipation, blurred vision, and cognitive effects — particularly concerning in older men. Mirabegron avoids most of these anticholinergic side effects, with hypertension being its primary concern.
Comparing Medications Head to Head
When choosing between BPH medications, several factors influence the decision:
Speed of relief matters. Alpha-blockers win decisively here, providing noticeable improvement within one to two weeks. 5-ARIs require months of patience. If symptoms are significantly affecting quality of life, starting with an alpha-blocker makes practical sense.
Prostate size influences drug choice. Men with larger prostates (greater than 40 grams) benefit more from 5-ARIs and combination therapy. Men with smaller prostates typically do well with alpha-blockers alone.
Sexual function priorities shape preferences. Alpha-blockers primarily affect ejaculation, while 5-ARIs are more likely to affect erection quality and libido. Tadalafil improves sexual function while treating BPH — a compelling advantage for sexually active men.
Long-term disease modification favors 5-ARIs. Only 5-ARIs and combination therapy have been shown to reduce the risk of acute urinary retention and the eventual need for surgery. Alpha-blockers relieve symptoms but do not change the natural progression of the disease.
Cost and insurance coverage vary. Generic tamsulosin and finasteride are inexpensive, often costing under $15 per month. Brand-name combinations and newer agents can cost significantly more.
When Medications Are Not Enough
Despite optimal medical therapy, some men continue to experience bothersome symptoms or develop complications such as recurrent urinary tract infections, bladder stones, or chronic urinary retention. In these situations, urologists discuss procedural options ranging from minimally invasive office-based treatments like UroLift and Rezum to traditional transurethral resection of the prostate (TURP).
The decision to move from medication to a procedure should be based on the severity of symptoms, their impact on quality of life, the presence of complications, and patient preference. Many men manage BPH successfully with medications for years or even decades.
Lifestyle Modifications That Complement Medication
Regardless of which medication you take, several behavioral strategies can improve BPH symptoms. Reducing fluid intake in the evening helps minimize nocturia. Limiting caffeine and alcohol, both bladder irritants, can reduce urgency and frequency. Timed voiding — urinating on a schedule rather than waiting for urgency — helps retrain the bladder.
Regular physical activity has been associated with reduced BPH symptom severity in observational studies. Maintaining a healthy weight is also important, as obesity is a risk factor for both BPH progression and more severe symptoms.
Some men find that certain over-the-counter medications worsen their BPH symptoms. Decongestants containing pseudoephedrine tighten the smooth muscle in the prostate and bladder neck, potentially causing acute urinary retention. Antihistamines with anticholinergic properties can also impair bladder function. Always inform your pharmacist about your BPH when purchasing cold or allergy medications.
Having the Conversation With Your Doctor
Before your urology appointment, track your symptoms for a week or two. Note how many times you urinate during the day and night, whether you experience urgency or leakage, and how your symptoms affect daily activities and sleep quality. The International Prostate Symptom Score questionnaire, which your doctor can provide, offers a standardized way to quantify your symptoms.
Ask your urologist about the size of your prostate (from a digital rectal exam or ultrasound), your PSA level, and any other factors that might influence which medication is best suited for your situation. Understanding these details helps you participate meaningfully in shared decision-making rather than passively accepting a prescription.
If sexual function is important to you — and for most men it is — raise this topic directly. Your doctor can tailor the treatment approach to minimize sexual side effects while still providing adequate symptom relief.
The Bottom Line
BPH medication is not one-size-fits-all. Alpha-blockers offer fast relief by relaxing prostate muscle, 5-ARIs provide long-term benefit by shrinking prostate tissue, and combination therapy delivers the advantages of both at the cost of more side effects. Newer options like daily tadalafil add flexibility, particularly for men dealing with both urinary and sexual symptoms.
The right medication depends on your prostate size, symptom severity, sexual function priorities, and willingness to accept certain side effects. Work closely with your urologist to find the approach that gives you the best balance of symptom relief and quality of life. And remember — BPH medications are a long-term commitment, not a quick fix. Staying consistent with your treatment and follow-up appointments is the key to managing this condition effectively over time.
Sources and Further Reading
Health and Beyond uses reputable medical and scientific sources where possible. These links support or expand on the topics discussed above.
- hypertensionmayoclinic.org
- American Urological Associationauanet.org
- New England Journal of Medicinenejm.org
